The potential use of daridorexant in eating disorders: beyond the treatment of insomnia?

IF 2.1 3区医学 Q3 PHARMACOLOGY & PHARMACY

International Clinical Psychopharmacology Pub Date : 2024-05-10 DOI:10.1097/YIC.0000000000000552

Alice Caldiroli, Letizia M Affaticati, Enrico Capuzzi, Davide La Tegola, Fabrizia Colmegna, Massimo Clerici, Antonios Dakanalis, Massimiliano Buoli

{"title":"The potential use of daridorexant in eating disorders: beyond the treatment of insomnia?","authors":"Alice Caldiroli, Letizia M Affaticati, Enrico Capuzzi, Davide La Tegola, Fabrizia Colmegna, Massimo Clerici, Antonios Dakanalis, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000552","DOIUrl":null,"url":null,"abstract":"<p><p>A strong interplay exists between sleep and dietary habits, and sleep disturbances have been repeatedly documented in individuals with eating disorders (EDs). The orexin system - implicated in sleep regulation, energy homeostasis, and food reward - may represent a mechanist link between sleep alterations and disordered eating behaviors. Daridorexant is a dual orexin receptor antagonist (DORA) recently approved for the treatment of insomnia, with demonstrated efficacy and tolerability. Owing to its action on orexin neurons, the compound represents an intriguing option for addressing both sleep-related and core symptoms of EDs. By inhibiting motor hyperactivity, daridorexant may reduce excessive physical exercise in individuals with anorexia nervosa (AN) restricting type. Additionally, the compound may exert anti-binge effects, suggesting broad applicability in binge ED, bulimia nervosa, and binge/purging AN. In this framework, daridorexant emerges as a promising therapeutic option, offering a multifaceted approach to improving circadian rhythms, energy balance, and overall quality of life in individuals with diverse ED subtypes.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/YIC.0000000000000552","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

A strong interplay exists between sleep and dietary habits, and sleep disturbances have been repeatedly documented in individuals with eating disorders (EDs). The orexin system - implicated in sleep regulation, energy homeostasis, and food reward - may represent a mechanist link between sleep alterations and disordered eating behaviors. Daridorexant is a dual orexin receptor antagonist (DORA) recently approved for the treatment of insomnia, with demonstrated efficacy and tolerability. Owing to its action on orexin neurons, the compound represents an intriguing option for addressing both sleep-related and core symptoms of EDs. By inhibiting motor hyperactivity, daridorexant may reduce excessive physical exercise in individuals with anorexia nervosa (AN) restricting type. Additionally, the compound may exert anti-binge effects, suggesting broad applicability in binge ED, bulimia nervosa, and binge/purging AN. In this framework, daridorexant emerges as a promising therapeutic option, offering a multifaceted approach to improving circadian rhythms, energy balance, and overall quality of life in individuals with diverse ED subtypes.

查看原文本刊更多论文

达立酮在饮食失调症中的潜在用途：超越失眠治疗？

睡眠与饮食习惯之间存在着强烈的相互作用，睡眠障碍已多次被记录在饮食失调（ED）患者的病例中。奥曲肽系统与睡眠调节、能量平衡和食物奖赏有关，它可能是睡眠改变与饮食失调行为之间的机理联系。Daridorexant 是一种双重奥曲肽受体拮抗剂（DORA），最近被批准用于治疗失眠症，其疗效和耐受性均已得到证实。由于其对奥曲肽神经元的作用，该化合物是解决睡眠相关症状和肥胖症核心症状的一个令人感兴趣的选择。通过抑制运动亢进，daridorexant 可减少神经性厌食症（AN）限制型患者的过度运动。此外，该化合物还可能具有抗暴饮暴食的作用，这表明它广泛适用于暴饮暴食性厌食症、神经性贪食症和暴饮暴食/暴食性厌食症。在这一框架下，daridorexant 成为一种很有前景的治疗选择，它提供了一种多方面的方法来改善昼夜节律、能量平衡和不同 ED 亚型患者的整体生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Clinical Psychopharmacology 医学-精神病学

CiteScore

4.40

自引率

23.10%

发文量

审稿时长

>12 weeks

期刊介绍： International Clinical Psychopharmacology provides an essential link between research and clinical practice throughout psychopharmacology. It reports on studies in human subjects, both healthy volunteers and patients, which relate the effects of drugs on psychological processes. A major objective of the journal is to publish fully refereed papers which throw light on the ways in which the study of psychotropic drugs can increase our understanding of psychopharmacology. To this end the journal publishes results of early Phase I and II studies, as well as those of controlled clinical trials of psychotropic drugs in Phase II and IV. Other topics covered include the epidemiology of psychotropic drug prescribing and drug taking, the sociology of psychotropic drugs including compliance, and research into the safety and adverse effects of these compounds.